Favipiravir
- Generic Name
- Favipiravir
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4FN3O2
- CAS Number
- 259793-96-9
- Unique Ingredient Identifier
- EW5GL2X7E0
- Background
Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. The antiviral targets RNA-dependent RNA polymerase (RdRp) enzymes, which are necessary for the transcription and replication of viral genomes.
Not only does favipiravir inhibit replication of influenza A and B, but the drug has shown promise in the treatment of avian influenza, and may be an alternative option for influenza strains that are resistant to neuramidase inhibitors. Favipiravir has been investigated for the treatment of life-threatening pathogens such as Ebola virus, Lassa virus, and now COVID-19.
- Indication
⑴用于埃博拉病毒感染的治疗。
⑵用于治疗成人新型或再次流行的流感（仅限于其他抗流感病毒药物治疗无效或效果不佳时使用）
- Associated Conditions
- Treatment resistant Novel Influenza, Treatment resistant Reemerging Influenza
Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
- Conditions
- COVID-19
- Interventions
- Drug: Nirmatrelvir/ritonavir (e.g. PAXLOVID™)Drug: Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™)Other: No treatmentDrug: Monoclonal antibodiesDrug: Molnupiravir
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 3800
- Registration Number
- NCT05041907
- Locations
- 🇳🇵
Sukraraj Tropical & Infectious Disease Hospital, Kathmandu, Nepal
🇧🇷Universidade Federal de Minas Gerais, Minas Gerais, Brazil
🇱🇦Laos-Oxford-Mahosot Wellcome Trust Research Unit, Vientiane, Lao People's Democratic Republic
Clinical Trial For Early SARS-CoV-2 (COVID-19) Treatment
- Conditions
- Covid19
- Interventions
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2021-07-29
- Lead Sponsor
- Health Institutes of Turkey
- Target Recruit Count
- 1120
- Registration Number
- NCT04981379
- Locations
- 🇹🇷
Ankara City Hospital, Ankara, Turkey
🇹🇷Istanbul University Istanbul Medicine Faculty, Istanbul, Turkey
🇹🇷Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, Istanbul, Turkey
Study to Assess the Efficacy and Safety of Favipiravir-HU
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- Interventions
- Drug: Placebo HU
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2022-11-09
- Lead Sponsor
- University of Pecs
- Target Recruit Count
- 1
- Registration Number
- NCT04940871
- Locations
- 🇭🇺
University of Szeged - Internal Medicine, Szeged, Hungary
Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19
- Conditions
- Covid19
- Interventions
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Coordinación de Investigación en Salud, Mexico
- Target Recruit Count
- 120
- Registration Number
- NCT04918927
- Locations
- 🇲🇽
Hospital de Infectología "Daniel Méndez Hernández" del Centro Médico Nacional La Raza, Ciudad de Mexico, Azcapotzalco, Mexico
Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Bernhard Nocht Institute for Tropical Medicine
- Target Recruit Count
- 40
- Registration Number
- NCT04907682
- Locations
- 🇳🇬
Federal Medical Center of Owo, Owo, Ondo State, Nigeria
🇳🇬Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria
Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- The Scientific and Technological Research Council of Turkey
- Target Recruit Count
- 100
- Registration Number
- NCT04828564
- Locations
- 🇹🇷
Ankara University, School of Medicine, Ankara, Cebeci, Turkey
🇹🇷Umraniye Training and Research Hospital, Istanbul, Turkey
🇹🇷Koc University Hospital, Istanbul, Turkey
Favipiravir in High-risk COVID-19 Patients
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Penang Hospital, Malaysia
- Target Recruit Count
- 500
- Registration Number
- NCT04818320
- Locations
- 🇲🇾
Penang General Hospital, George Town, Pulau Pinang, Malaysia
Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection
- Conditions
- COVID-19 Infection
- Interventions
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 205
- Registration Number
- NCT04784559
- Locations
- 🇧🇷
Hospital Felicio Rocho, Belo Horizonte, MG, Brazil
🇲🇽Universidad Autonoma de Nuevo Leon - Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, NL, Mexico
🇷🇴Institutul National De Boli Infectioase "Prof. Dr. Matei Bals", Bucharest, Romania
AGILE (Early Phase Platform Trial for COVID-19)
- Conditions
- Covid19
- Interventions
- Drug: MolnupiravirDrug: NHS standard of care as per COVID-19 treatment guidelinesDrug: Paxlovid
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- University of Liverpool
- Target Recruit Count
- 600
- Registration Number
- NCT04746183
- Locations
- 🇬🇧
Manchester University NHS Foundation Trust, Manchester, United Kingdom
🇿🇦Desmond Tutu Health Foundation, Cape Town, South Africa
🇿🇦Ezintsha, Johannesburg, South Africa
Antiviral Drugs on the Treatment of SARS-CoV-2
- Conditions
- Pneumonia, ViralComplication of Medical Care
- Interventions
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Astana Medical University
- Target Recruit Count
- 150
- Registration Number
- NCT04727775
- Locations
- 🇰🇿
Semey Medical University, Semey, Kazakhstan
🇰🇿Aidos Konkaev, Astana, Kazakhstan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.